Y
Young Tomothy John
Researcher at Vertex Pharmaceuticals
Publications - 4
Citations - 708
Young Tomothy John is an academic researcher from Vertex Pharmaceuticals. The author has contributed to research in topics: Cystic fibrosis transmembrane conductance regulator & Ivacaftor. The author has an hindex of 3, co-authored 4 publications receiving 500 citations.
Papers
More filters
Journal ArticleDOI
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Dominic Keating,Gautham Marigowda,Lucy D. Burr,Cori L. Daines,Marcus A. Mall,Edward F. McKone,Bonnie W. Ramsey,Steven M. Rowe,Laura A. Sass,Elizabeth Tullis,Charlotte M. McKee,Samuel M. Moskowitz,Sarah Robertson,Jessica H. Savage,Christopher Simard,Fredrick Van Goor,David Waltz,Fengjuan Xuan,Young Tomothy John,Jennifer L. Taylor-Cousar +19 more
TL;DR: The use of VX‐445–tezacaftor–ivacaftor to target Phe508del CFTR protein resulted in increased CFTR function in vitro and translated to improvements in patients with cystic fibrosis with one or two Phe48del alleles.
Journal ArticleDOI
VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles
Jane C. Davies,Samuel M. Moskowitz,Cynthia A. Brown,Alex Horsley,Marcus A. Mall,Edward F. McKone,Barry J. Plant,Dario Prais,Bonnie W. Ramsey,Jennifer L. Taylor-Cousar,Elizabeth Tullis,Ahmet Uluer,Charlotte M. McKee,Sarah A. Robertson,Rebecca A. Shilling,Christopher Simard,Fredrick Van Goor,David Waltz,Fengjuan Xuan,Young Tomothy John,Steven M. Rowe +20 more
TL;DR: Robust in vitro activity of VX‐659–tezacaftor–ivacaftor targeting P he508del CFTR protein translated into improvements for patients with Phe508del–MF or Phe484del–Phe50del genotypes.
Patent
Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulator
Abela Alexander Russell,Alcacio Timothy,Corey Anderson,Angell Paul Timothy,Baek Minson,Jeremy J. Clemens,Cleveland Thomas,Ferris Lori Ann,Peter D. J. Grootenhuis,Raymond S. Gross,Gulevich Anton,Ruah Sara S Hadida,Hsia Clara Kuang-Ju,Robert Michael Hughes,Pramod Joshi,Kang Ping,Ali Keshavarz-Shokri,Khatuya Haripada,Paul Krenitsky,Mccartney Jason,Mark Miller,Paraselli Prasuna,Pierre Fabrice Jean Denis,Yi Shi,Shrestha Muna,Siesel David Andrew,Stavropoulos Kathy,Andreas Termin,Fredrick Van Goor,Uy Johnny,Young Tomothy John,Jinglan Zhou +31 more
TL;DR: In this paper, the authors have disclosed the composition of compounds of formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any compound, and metabolites of any of the foregoing.
Patent
Crystalline form of a n-(pyrazol-4-yl)sulfonyl-6-(pyrazol-1-yl)-2-(pyrrolidin-1-yl)pyridine-3-carboxamide for treating cystic fibrosis
Abela Alexander Russell,Alcacio Timothy,Corey Anderson,Angell Paul Timothy,Baek Minson,Jeremy J. Clemens,Cleveland Thomas,Ferris Lori Ann,Grootenhuis Peter D J,Raymond S. Gross,Gulevich Anton,Hadida Ruah Sara Sabina,Hsia Clara Kuang-Ju,Hughes Robert M,Joshi Pramod Virupax,Kang Ping,Ali Keshavarz-Shokri,Khatuya Haripada,Paul Krenitsky,Mccartney Jason,Mark Miller,Paraselli Prasuna,Pierre Fabrice Jean Denis,Shi Yi,Shrestha Muna,Siesel David Andrew,Stavropoulos Kathy,Andreas P. Termin,Uy Johnny,Van Goor Fredrick F,Young Tomothy John,Zhou Jinglan +31 more
TL;DR: In this paper, solid state forms of Compound 1 and salts and solvates thereof are also disclosed, as well as a method for treating cystic fibrosis using the same, and methods for making the same.